KPE 02001003

Drug Profile

KPE 02001003

Alternative Names: KPE02001003; KPE02003002

Latest Information Update: 18 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
  • Developer Kemin Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Dec 2008 No development reported - Phase-II for Hepatitis C in Belgium (unspecified route)
  • 13 Jan 2005 KPE 02001003 is available for licensing worldwide (http://www.kemin.com)
  • 15 Jan 2004 Phase-II clinical trials in Hepatitis C treatment in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top